LGND
Price
$170.65
Change
-$0.12 (-0.07%)
Updated
Sep 23 closing price
Capitalization
3.33B
42 days until earnings call
OCUL
Price
$12.25
Change
+$0.05 (+0.41%)
Updated
Sep 23 closing price
Capitalization
2.13B
47 days until earnings call
Interact to see
Advertisement

LGND vs OCUL

Header iconLGND vs OCUL Comparison
Open Charts LGND vs OCULBanner chart's image
Ligand Pharmaceuticals
Price$170.65
Change-$0.12 (-0.07%)
Volume$133.77K
Capitalization3.33B
Ocular Therapeutix
Price$12.25
Change+$0.05 (+0.41%)
Volume$2M
Capitalization2.13B
LGND vs OCUL Comparison Chart in %
Loading...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LGND vs. OCUL commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LGND is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (LGND: $170.65 vs. OCUL: $12.25)
Brand notoriety: LGND and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LGND: 52% vs. OCUL: 92%
Market capitalization -- LGND: $3.33B vs. OCUL: $2.13B
LGND [@Biotechnology] is valued at $3.33B. OCUL’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LGND’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • LGND’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, LGND is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LGND’s TA Score shows that 3 TA indicator(s) are bullish while OCUL’s TA Score has 4 bullish TA indicator(s).

  • LGND’s TA Score: 3 bullish, 5 bearish.
  • OCUL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than LGND.

Price Growth

LGND (@Biotechnology) experienced а +2.65% price change this week, while OCUL (@Biotechnology) price change was -1.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.

Reported Earning Dates

LGND is expected to report earnings on Nov 05, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LGND($3.33B) has a higher market cap than OCUL($2.13B). LGND YTD gains are higher at: 59.263 vs. OCUL (43.443). LGND has higher annual earnings (EBITDA): -45.94M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. LGND (255M). LGND has less debt than OCUL: LGND (5.74M) vs OCUL (76.9M). LGND has higher revenues than OCUL: LGND (188M) vs OCUL (56.7M).
LGNDOCULLGND / OCUL
Capitalization3.33B2.13B156%
EBITDA-45.94M-200.5M23%
Gain YTD59.26343.443136%
P/E Ratio46.19N/A-
Revenue188M56.7M332%
Total Cash255M391M65%
Total Debt5.74M76.9M7%
FUNDAMENTALS RATINGS
LGND vs OCUL: Fundamental Ratings
LGND
OCUL
OUTLOOK RATING
1..100
6483
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
3984
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
3941
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (52) in the Pharmaceuticals Other industry is in the same range as LGND (73) in the Biotechnology industry. This means that OCUL’s stock grew similarly to LGND’s over the last 12 months.

LGND's Profit vs Risk Rating (39) in the Biotechnology industry is somewhat better than the same rating for OCUL (84) in the Pharmaceuticals Other industry. This means that LGND’s stock grew somewhat faster than OCUL’s over the last 12 months.

LGND's SMR Rating (95) in the Biotechnology industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that LGND’s stock grew similarly to OCUL’s over the last 12 months.

LGND's Price Growth Rating (39) in the Biotechnology industry is in the same range as OCUL (41) in the Pharmaceuticals Other industry. This means that LGND’s stock grew similarly to OCUL’s over the last 12 months.

LGND's P/E Growth Rating (90) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that LGND’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LGNDOCUL
RSI
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 14 days ago
75%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
73%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RREAX29.580.15
+0.51%
Russell Inv Global Real Estate Secs A
STREX22.21N/A
N/A
Sterling Capital Equity Income R6
JSEQX53.27-0.20
-0.37%
JPMorgan Small Cap Equity R4
FNEFX75.36-0.42
-0.55%
American Funds New Economy F3
ETIEX14.80-0.12
-0.80%
Eventide Exponential Technologies I

LGND and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with AGIO. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
-0.07%
AGIO - LGND
49%
Loosely correlated
-0.84%
CRSP - LGND
47%
Loosely correlated
-2.16%
SYRE - LGND
47%
Loosely correlated
+4.77%
ACLX - LGND
45%
Loosely correlated
+1.19%
OCUL - LGND
44%
Loosely correlated
+0.41%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+0.41%
EYPT - OCUL
65%
Loosely correlated
+0.22%
NRIX - OCUL
56%
Loosely correlated
-2.25%
IDYA - OCUL
56%
Loosely correlated
+0.04%
CRNX - OCUL
55%
Loosely correlated
+6.35%
IMVT - OCUL
55%
Loosely correlated
-4.43%
More